International Nonproprietary Names Expert Committee Of The World Health Organization Has Selected Labafenogene Marselecobac As The Nonproprietary Name Of Synlogic's Investigational Drug For Phenylketonuria, Formerly SYNB1934
Portfolio Pulse from Benzinga Newsdesk
The World Health Organization's International Nonproprietary Names Expert Committee has chosen Labafenogene Marselecobac as the nonproprietary name for Synlogic's investigational drug for Phenylketonuria, previously known as SYNB1934.
June 28, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synlogic's investigational drug for Phenylketonuria has been given a nonproprietary name by the WHO's committee, indicating progress in its development.
The naming of Synlogic's investigational drug by the WHO's committee is a positive sign, indicating that the drug is progressing in its development and regulatory process. This could potentially boost investor confidence in Synlogic and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100